Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin

References

• Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37
   PubMed Web of Science ®Google Scholar
• Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med 1985;78:32-7
   PubMed Web of Science ®Google Scholar
• Popovic JR. 1999 National hospital discharge survey: annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2001;151:1-206
   Google Scholar
• Morston BJ, Plouffe JF, Breiman RF, et al. Preliminary findings in a community-based pneumonia incidence study. In: Barbaree JM, Breiman RF, Dufour AP (eds.) Legionella: Current Status and Emerging Perspectives. Washington, DC: American Society for Microbiology, 1993: 36-7
   Google Scholar
• Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-24
   PubMed Web of Science ®Google Scholar
• Colice GL, Morley MA, Asche C, et al. Treatment costs of community-acquired pneumonia in an employed population. CHEST 2004;125:2140-45
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007;44:S27-S72
   PubMed Web of Science ®Google Scholar
• Hurst M, Lamb HM, Scott LJ, et al. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 2002;62:2127-67
   PubMed Web of Science ®Google Scholar
• Gunderson BW, Ross GH, Ibrahim KH, et al. What do we really know about antibiotic pharmacodynamics?. Pharmacotherapy 2001;2l:S302-S318
   Google Scholar
• Liu HH. Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia. Curr Therapeut Res 2004;65:225-38
   PubMed Web of Science ®Google Scholar
• Schein J, Janagap-Benson C, Grant R, et al. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay. Curr Med Res Opin 2008;24:895-906
   PubMed Web of Science ®Google Scholar
• Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001;110:451–7
   PubMed Web of Science ®Google Scholar
• Capelastegui A, Espana PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004;39:955–63
   PubMed Web of Science ®Google Scholar
• Ye X, Sikirica V, Schein JR, et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008;30:358-71
   PubMed Web of Science ®Google Scholar
• Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
   PubMedGoogle Scholar
• Mandell LA, Bartlett JG, Dowell SF, et al. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Erard V, Cometta A, et al. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J 2004;24:644-48
   PubMed Web of Science ®Google Scholar
• D’Ignazio J, Camere MA, Lewis DE, et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005;49:4035–41
   PubMed Web of Science ®Google Scholar
• Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly Study Group. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006;42:73-81
   PubMed Web of Science ®Google Scholar
• Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262-70
   PubMed Web of Science ®Google Scholar
• Lavoie F, Blais L, Castilloux A-M, et al. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB). Can J Clin Pharmacol 2005;12:e212-e217
   PubMedGoogle Scholar